Dr. Scheinberg is a physician-scientist who specializes in the care of patients with leukemia and is also investigating new therapeutic approaches to cancer, both in the clinic and in the laboratory. His research is focused on discovering and developing novel, specific immunotherapeutic agents. These include monoclonal antibodies that target the cell surface of cancers, intracellular proteins, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, targeted nanodevices that selectively kill cancer cells, and therapeutic vaccines that target the oncogene products that cause the cancers.
Eight different therapeutic agents developed by Dr. Scheinberg in his laboratory have reached human clinical trials, including the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg has published more than 290 papers, chapters, and books in these fields.
Dr. Scheinberg currently holds the Vincent Astor Chair at Memorial Sloan Kettering and is Chair of the Molecular Pharmacology Program in the Sloan Kettering Institute. He also founded and chairs the Experimental Therapeutics and formerly the Nanotechnology Center at MSK. He is a professor of medicine and pharmacology and co-chair of the pharmacology graduate program at Weill-Cornell Medical College and a professor at the Gerstner Sloan Kettering Graduate School. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Cornell, and Rockefeller Universities.
From 1992 until 2003, Dr. Scheinberg was Chief of the Leukemia Service in Memorial Hospital. He has been elected into the American Society of Clinical Investigation, the American Association of Physicians, and the Interurban Club. His other awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, the Leukemia and Lymphoma Society Translational Investigator Awards, and CapCure Awards. He is an advisor to charitable foundations, cancer centers, and biotech companies.
- Clinical Expertise: Acute and Chronic Leukemias; Immunotherapy; Monoclonal Antibodies; Cancer Vaccines
- Languages Spoken: English
- Education: MD, PhD, The Johns Hopkins School of Medicine
- Residencies: The New York Hospital/Cornell Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more